Post I made in response to a WAG somebody made regarding

New Post Public Reply Private Reply Replies (2) Message Board
petemantx
1,074
Post I made in response to a WAG somebody made regarding value of deal for Brilacidin or IPIX. I didn't get into any numbers as I wanted to simply stress why the value should be way up there, beyond anything seen w/ startups in the past:

Some may say that your estimate for a deal sounds way too lucrative for IPIX based on past deals for bio startups but I fall in line more with you for the following reasons:

1. BP will have bypassed ALL RISK for the drug in both its safety profile and its efficacy shown by all trials to date.

2. BP has RBL investigational support that B should be able to handle not just Covid but ALL corona viruses to include Flu, HIV, Herpes, and more. These revenue streams are huge. It has also shown B should work not just on enveloped viruses but also non-enveloped viruses. This includes those viruses normally affecting young children. Again, more large revenue streams.

3. RBL testing has also shown that B should be a leading candidate to the DOD as a primary defense against all biological and viral attacks on American forces. This is supported in that to date B has not seen a bacteria or virus it cannot kill. 3 RBLs have been testing B now for over a year and the success is shown in that B was to be a topic presented at the major DOD Biological Defense meeting in Orlando in June that had to be cancelled due to Covid. It should be noted that all 3 RBLs plan on issuing peer review papers on their findings - major success right there.

4. Being anti-inflammatory, major lung related revenue streams become a strong possibility (COPD, Asthma, Bronchitis) and also for MANY more issues such as encephalitis.

5. B has shown a propensity to cure most all ailments in the GI tract and this will be confirmed soon when the UC trial results are achieved. Again, very large revenue streams being attacked by B.

6. B has been said to have many more areas it should be able to target that have as yet to be found but are strong areas for positive expectations (Example: "leaky gut is expected to be handled by B and leaky gut has now been linked to 'leaky brain' which should also be a promising target and in here we are talking about Parkinson's Disease, Lou Gehrig's Disease (ALS), Alzheimer's, and dementia). Another major area are all auto-immune problems, kidney, and liver problems.

7. To date B has shown an excellent ability to transfer in vitro results into in vivo results so all the above areas mentioned above are not just pipe dreams but very realistic areas that B should prove a leading factor in solving for medicine.

8. The above are just for the revenues based on the "small molecule" targets for Brilacidin. The "polymer" revenue possibilities (polymer being many small molecules linked together to form strings of B) in industrial products to include paints, textiles, plastics, etc. is astounding and I wouldn't even hazard a guess as to where these numbers could lead but it is large.

Now add all the above revenue streams and you are talking hundreds of billions a year. So if the total is $200B/yr and B only gets 5% of the market (which IMO is ridiculously low) that is $10B/yr and the upside could be $50B+/yr.

Remember, we are not talking just a drug but a new arm of medicine and that is what separates the abilities of B to all other drugs.

The numbers above are simply for B. I have not even addressed the potential of Kevetrin and it could be a monster stand alone and/or complementary drug for cancer treatments. It has revenue potential way, way up in the tens of billions, or more.

So add up the possibilities, the lack of risk, the already successful findings for Covid (once successful top line results are released this week or next), and the safety of the drug and what you project is a seemingly paltry amount IMO.

I feel whoever gets the Brilacidin platform is not just buying a drug but is attaining the library of a big pharma in the multitude of major revenue streams it will be able to target.

1

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

DKSH's Vietnam Oncology Pact Carries Real Promise, Risk

Updated Category News Views 58

A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 318

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 140

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 110

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 61

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 455

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 661

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 394

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading

Top 5 Most Recently Viewed Articles

Shaquille O'Neal Empowers Young Leaders with New Scholarship

Updated Category News Views 743

Shaquille O'Neal Champions the Future of Entrepreneurship Full scholarships, elite mentorship, and real-world learning experiences are now within reach for aspiring creators and entrepreneurs, thanks to a groundbreaking initiative launched by Campus, a modern two-year college committed to nurturing the next generation of leaders. This new scholarship program, backed by...

Continue Reading
Investors Take Action: Class Action Lawsuits on the Rise

Updated Category News Views 146

Protecting Your Investments: Class Action Overview Investing in public companies often comes with risks, and sometimes those risks manifest as legal issues. Recently, class action lawsuits have sprung up involving several well-known companies. These lawsuits present opportunities for investors to raise their voices against corporate misconduct and reclaim lost...

Continue Reading
Top Strategies from DealerFire to Enhance Website Engagement

Updated Category News Views 171

Effective Strategies to Reduce Dealership Website Bounce Rates Transforming website visitors into clients is essential for dealerships, and DealerFire offers insightful strategies to enhance website performance effectively. Boosting Page Load Speed The Importance of Speed Website speed plays a critical role in keeping visitors on the site. DealerFire stresses the need to...

Continue Reading
Lassila & Tikanoja's Annual General Meeting Announcement

Updated Category News Views 115

Notice of the Annual General Meeting Lassila & Tikanoja plc has issued a notice regarding the upcoming Annual General Meeting. This meeting serves as an important gathering for shareholders to discuss significant matters concerning the company's future. Meeting Details The Annual General Meeting will take place on Thursday, March 27, 2025, at 4:00 PM, with registration...

Continue Reading
Soapy Joe's Expands Its Reach with 25th Car Wash Location

Updated Category News Views 490

Soapy Joe's Expands Its Reach with 25th Car Wash Location Soapy Joe's Car Wash, a family-owned favorite in the San Diego area, is thrilled to announce the arrival of its 25th location in the community. This new car wash is positioned to provide not only top-notch car cleaning services but also a unique, enjoyable experience for local residents. Grand Opening Celebration...

Continue Reading